85 related articles for article (PubMed ID: 26394771)
1. Risk-adapted strategies for the treatment of Hodgkin lymphoma.
Keller J; Carson KR
Expert Opin Drug Saf; 2015 Oct; 14(10):1519-30. PubMed ID: 26394771
[TBL] [Abstract][Full Text] [Related]
2. SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
Watkins MP; Fanale MA; Bartlett NL
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):81-90. PubMed ID: 29366607
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
Kostakoglu L; Evens AM
Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.
Eichenauer DA; Böll B; Diehl V
Expert Opin Pharmacother; 2014 Jun; 15(8):1139-51. PubMed ID: 24749840
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
Hutchings M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
[TBL] [Abstract][Full Text] [Related]
6. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
Romano A; Parrinello NL; Vetro C; Forte S; Chiarenza A; Figuera A; Motta G; Palumbo GA; Ippolito M; Consoli U; Di Raimondo F
Br J Haematol; 2015 Mar; 168(5):689-700. PubMed ID: 25376846
[TBL] [Abstract][Full Text] [Related]
7. Treatment of newly diagnosed advanced stage Hodgkin lymphoma.
Uhm J; Kuruvilla J
Blood Rev; 2012 Jul; 26(4):167-74. PubMed ID: 22542250
[TBL] [Abstract][Full Text] [Related]
8. Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Cochrane T; Campbell BA; Gangatharan SA; Latimer M; Khor R; Christie DRH; Gilbertson M; Ratnasingam S; Palfreyman E; Lee HP; Trotman J; Hertzberg M; Dickinson M
Intern Med J; 2021 Dec; 51(12):2119-2128. PubMed ID: 34505342
[TBL] [Abstract][Full Text] [Related]
9. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
[TBL] [Abstract][Full Text] [Related]
10. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL
Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin lymphoma.
Gobbi PG; Ferreri AJ; Ponzoni M; Levis A
Crit Rev Oncol Hematol; 2013 Feb; 85(2):216-37. PubMed ID: 22867814
[TBL] [Abstract][Full Text] [Related]
12. Modern treatment of Hodgkin lymphoma.
Bartlett NL
Curr Opin Hematol; 2008 Jul; 15(4):408-14. PubMed ID: 18536581
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin's lymphoma therapy: past, present, and future.
Rathore B; Kadin ME
Expert Opin Pharmacother; 2010 Dec; 11(17):2891-906. PubMed ID: 21050034
[TBL] [Abstract][Full Text] [Related]
14. Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents.
Giulino-Roth L; Keller FG; Hodgson DC; Kelly KM
Br J Haematol; 2015 Jun; 169(5):647-60. PubMed ID: 25824371
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
16. An update on disease biomarkers for Hodgkin lymphoma.
Cirillo M; Borchmann S
Expert Rev Hematol; 2020 May; 13(5):481-488. PubMed ID: 32193957
[No Abstract] [Full Text] [Related]
17. Progress in the initial management of Hodgkin's Lymphoma.
Marri PR; Ansell SM
Transfus Apher Sci; 2013 Aug; 49(1):12-8. PubMed ID: 23769695
[TBL] [Abstract][Full Text] [Related]
18. The role of PET in first-line treatment of Hodgkin lymphoma.
Trotman J; Barrington SF
Lancet Haematol; 2021 Jan; 8(1):e67-e79. PubMed ID: 33357485
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin lymphoma in Tyrol-a population-based study.
Fong D; Steurer M; Greil R; Gunsilius E; Spizzo G; Gastl G; Tzankov A
Ann Hematol; 2009 May; 88(5):449-56. PubMed ID: 18846373
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2014 Jul; 89(7):771-9. PubMed ID: 24953862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
